The WACC of CytomX Therapeutics Inc (CTMX) is 8.6%.
| Range | Selected | |
| Cost of equity | 10.90% - 14.20% | 12.55% |
| Tax rate | 0.40% - 12.30% | 6.35% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 7.9% - 9.3% | 8.6% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 1.53 | 1.67 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 10.90% | 14.20% |
| Tax rate | 0.40% | 12.30% |
| Debt/Equity ratio | 1 | 1 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 7.9% | 9.3% |
| Selected WACC | 8.6% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for CTMX:
cost_of_equity (12.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.53) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.